APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Non-Insulin Hypoglycemic Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Non-Insulin Hypoglycemic Drug Market Outlook and Growth Opportunities 2026

Report ID 174017590430 December 2025205 pages

Choose your research edition.

Industry ResearchNon-Insulin Hypoglycemic Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-Insulin Hypoglycemic Drug Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Non-Insulin Hypoglycemic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-Insulin Hypoglycemic Drug Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-Insulin Hypoglycemic Drug Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Non-Insulin Hypoglycemic Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Non-Insulin Hypoglycemic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non-Insulin Hypoglycemic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-Insulin Hypoglycemic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Non-Insulin Hypoglycemic Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Non-Insulin Hypoglycemic Drug market include GSK, Takeda, Merck, Uni-Bio Science Group, Eli Lilly, Jiangsu Hengrui Medicine, Jiangsu Hansoh Pharmaceutical, Pfizer and Sumitomo Dainippon Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Non-Insulin Hypoglycemic Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non-Insulin Hypoglycemic Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non-Insulin Hypoglycemic Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Non-Insulin Hypoglycemic Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Non-Insulin Hypoglycemic Drug Segment by Company

GSK

Takeda

Merck

Uni-Bio Science Group

Eli Lilly

Jiangsu Hengrui Medicine

Jiangsu Hansoh Pharmaceutical

Pfizer

Sumitomo Dainippon Pharma

Servier

Novo Nordisk

Luye Pharma Group

Intarcia Therapeutics

Geropharm

Eurofarma

Emisphere

Dong-A Pharmaceutical

Alkem Labs

3SBio

Non-Insulin Hypoglycemic Drug Segment by Type

Alpha Glucosidase Inhibitors

Meglitinides

Sulfonylureas

Thiazolidinediones

Biguanides

Others

Non-Insulin Hypoglycemic Drug Segment by Application

Hospital Pharmacies

Retail Pharmacies

Non-Insulin Hypoglycemic Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Non-Insulin Hypoglycemic Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Non-Insulin Hypoglycemic Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Non-Insulin Hypoglycemic Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Non-Insulin Hypoglycemic Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Insulin Hypoglycemic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-Insulin Hypoglycemic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Insulin Hypoglycemic Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Non-Insulin Hypoglycemic Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-Insulin Hypoglycemic Drug industry.

Chapter 3: Detailed analysis of Non-Insulin Hypoglycemic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Non-Insulin Hypoglycemic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Non-Insulin Hypoglycemic Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Non-Insulin Hypoglycemic Drug Industry Trends Table 2. Non-Insulin Hypoglycemic Drug Industry Drivers Table 3. Non-Insulin Hypoglycemic Drug Industry Opportunities and Challenges Table 4. Non-Insulin Hypoglycemic Drug Industry Restraints Table 5. Global Non-Insulin Hypoglycemic Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Non-Insulin Hypoglycemic Drug Revenue Share by Company (2021-2026) Table 7. Global Non-Insulin Hypoglycemic Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Non-Insulin Hypoglycemic Drug Sales Volume Share by Company (2021-2026) Table 9. Global Non-Insulin Hypoglycemic Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Non-Insulin Hypoglycemic Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Non-Insulin Hypoglycemic Drug Key Company Manufacturing Base & Headquarters Table 12. Global Non-Insulin Hypoglycemic Drug Company, Product Type & Application Table 13. Global Non-Insulin Hypoglycemic Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Non-Insulin Hypoglycemic Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Alpha Glucosidase Inhibitors Table 18. Significant Companies of Meglitinides Table 19. Significant Companies of Sulfonylureas Table 20. Significant Companies of Thiazolidinediones Table 21. Significant Companies of Biguanides Table 22. Significant Companies of Others Table 23. Global Non-Insulin Hypoglycemic Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Non-Insulin Hypoglycemic Drug Sales Volume by Type (2021-2026) & (K Units) Table 25. Global Non-Insulin Hypoglycemic Drug Sales Volume by Type (2027-2032) & (K Units) Table 26. Global Non-Insulin Hypoglycemic Drug Sales Volume Share by Type (2021-2026) Table 27. Global Non-Insulin Hypoglycemic Drug Sales Volume Share by Type (2027-2032) Table 28. Global Non-Insulin Hypoglycemic Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Non-Insulin Hypoglycemic Drug Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Non-Insulin Hypoglycemic Drug Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Non-Insulin Hypoglycemic Drug Sales Value Share by Type (2021-2026) Table 32. Global Non-Insulin Hypoglycemic Drug Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Hospital Pharmacies Table 34. Significant Companies of Retail Pharmacies Table 35. Global Non-Insulin Hypoglycemic Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Non-Insulin Hypoglycemic Drug Sales Volume by Application (2021-2026) & (K Units) Table 37. Global Non-Insulin Hypoglycemic Drug Sales Volume by Application (2027-2032) & (K Units) Table 38. Global Non-Insulin Hypoglycemic Drug Sales Volume Share by Application (2021-2026) Table 39. Global Non-Insulin Hypoglycemic Drug Sales Volume Share by Application (2027-2032) Table 40. Global Non-Insulin Hypoglycemic Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Non-Insulin Hypoglycemic Drug Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Non-Insulin Hypoglycemic Drug Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Non-Insulin Hypoglycemic Drug Sales Value Share by Application (2021-2026) Table 44. Global Non-Insulin Hypoglycemic Drug Sales Value Share by Application (2027-2032) Table 45. Global Non-Insulin Hypoglycemic Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global Non-Insulin Hypoglycemic Drug Sales by Region (2021-2026) & (K Units) Table 47. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2021-2026) Table 48. Global Non-Insulin Hypoglycemic Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region (2027-2032) Table 50. Global Non-Insulin Hypoglycemic Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Non-Insulin Hypoglycemic Drug Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Non-Insulin Hypoglycemic Drug Sales Value Share by Region (2021-2026) Table 53. Global Non-Insulin Hypoglycemic Drug Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Non-Insulin Hypoglycemic Drug Sales Value Share by Region (2027-2032) Table 55. Global Non-Insulin Hypoglycemic Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Non-Insulin Hypoglycemic Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Non-Insulin Hypoglycemic Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. Global Non-Insulin Hypoglycemic Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026) & (K Units) Table 60. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2021-2026) Table 61. Global Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032) & (K Units) Table 62. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Country (2027-2032) Table 63. Global Non-Insulin Hypoglycemic Drug Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Non-Insulin Hypoglycemic Drug Sales Value Market Share by Country (2021-2026) Table 65. Global Non-Insulin Hypoglycemic Drug Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Non-Insulin Hypoglycemic Drug Sales Value Market Share by Country (2027-2032) Table 67. GSK Company Information Table 68. GSK Business Overview Table 69. GSK Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. GSK Non-Insulin Hypoglycemic Drug Product Portfolio Table 71. GSK Recent Development Table 72. Takeda Company Information Table 73. Takeda Business Overview Table 74. Takeda Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Takeda Non-Insulin Hypoglycemic Drug Product Portfolio Table 76. Takeda Recent Development Table 77. Merck Company Information Table 78. Merck Business Overview Table 79. Merck Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Merck Non-Insulin Hypoglycemic Drug Product Portfolio Table 81. Merck Recent Development Table 82. Uni-Bio Science Group Company Information Table 83. Uni-Bio Science Group Business Overview Table 84. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Portfolio Table 86. Uni-Bio Science Group Recent Development Table 87. Eli Lilly Company Information Table 88. Eli Lilly Business Overview Table 89. Eli Lilly Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Eli Lilly Non-Insulin Hypoglycemic Drug Product Portfolio Table 91. Eli Lilly Recent Development Table 92. Jiangsu Hengrui Medicine Company Information Table 93. Jiangsu Hengrui Medicine Business Overview Table 94. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Portfolio Table 96. Jiangsu Hengrui Medicine Recent Development Table 97. Jiangsu Hansoh Pharmaceutical Company Information Table 98. Jiangsu Hansoh Pharmaceutical Business Overview Table 99. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio Table 101. Jiangsu Hansoh Pharmaceutical Recent Development Table 102. Pfizer Company Information Table 103. Pfizer Business Overview Table 104. Pfizer Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Pfizer Non-Insulin Hypoglycemic Drug Product Portfolio Table 106. Pfizer Recent Development Table 107. Sumitomo Dainippon Pharma Company Information Table 108. Sumitomo Dainippon Pharma Business Overview Table 109. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Portfolio Table 111. Sumitomo Dainippon Pharma Recent Development Table 112. Servier Company Information Table 113. Servier Business Overview Table 114. Servier Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Servier Non-Insulin Hypoglycemic Drug Product Portfolio Table 116. Servier Recent Development Table 117. Novo Nordisk Company Information Table 118. Novo Nordisk Business Overview Table 119. Novo Nordisk Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Novo Nordisk Non-Insulin Hypoglycemic Drug Product Portfolio Table 121. Novo Nordisk Recent Development Table 122. Luye Pharma Group Company Information Table 123. Luye Pharma Group Business Overview Table 124. Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Portfolio Table 126. Luye Pharma Group Recent Development Table 127. Intarcia Therapeutics Company Information Table 128. Intarcia Therapeutics Business Overview Table 129. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 130. Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Portfolio Table 131. Intarcia Therapeutics Recent Development Table 132. Geropharm Company Information Table 133. Geropharm Business Overview Table 134. Geropharm Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 135. Geropharm Non-Insulin Hypoglycemic Drug Product Portfolio Table 136. Geropharm Recent Development Table 137. Eurofarma Company Information Table 138. Eurofarma Business Overview Table 139. Eurofarma Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 140. Eurofarma Non-Insulin Hypoglycemic Drug Product Portfolio Table 141. Eurofarma Recent Development Table 142. Emisphere Company Information Table 143. Emisphere Business Overview Table 144. Emisphere Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 145. Emisphere Non-Insulin Hypoglycemic Drug Product Portfolio Table 146. Emisphere Recent Development Table 147. Dong-A Pharmaceutical Company Information Table 148. Dong-A Pharmaceutical Business Overview Table 149. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 150. Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio Table 151. Dong-A Pharmaceutical Recent Development Table 152. Alkem Labs Company Information Table 153. Alkem Labs Business Overview Table 154. Alkem Labs Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 155. Alkem Labs Non-Insulin Hypoglycemic Drug Product Portfolio Table 156. Alkem Labs Recent Development Table 157. 3SBio Company Information Table 158. 3SBio Business Overview Table 159. 3SBio Non-Insulin Hypoglycemic Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 160. 3SBio Non-Insulin Hypoglycemic Drug Product Portfolio Table 161. 3SBio Recent Development Table 162. Key Raw Materials Table 163. Raw Materials Key Suppliers Table 164. Non-Insulin Hypoglycemic Drug Distributors List Table 165. Non-Insulin Hypoglycemic Drug Customers List Table 166. Research Programs/Design for This Report Table 167. Authors List of This Report Table 168. Secondary Sources Table 169. Primary Sources List of Figures Figure 1. Non-Insulin Hypoglycemic Drug Product Image Figure 2. Global Non-Insulin Hypoglycemic Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-Insulin Hypoglycemic Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Non-Insulin Hypoglycemic Drug Sales (2021-2032) & (K Units) Figure 5. Global Non-Insulin Hypoglycemic Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Non-Insulin Hypoglycemic Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Alpha Glucosidase Inhibitors Image Figure 10. Meglitinides Image Figure 11. Sulfonylureas Image Figure 12. Thiazolidinediones Image Figure 13. Biguanides Image Figure 14. Others Image Figure 15. Global Non-Insulin Hypoglycemic Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Non-Insulin Hypoglycemic Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Non-Insulin Hypoglycemic Drug Sales Volume Share by Type (2021-2032) Figure 18. Global Non-Insulin Hypoglycemic Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Non-Insulin Hypoglycemic Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Non-Insulin Hypoglycemic Drug Sales Value Share by Type (2021-2032) Figure 21. Hospital Pharmacies Image Figure 22. Retail Pharmacies Image Figure 23. Global Non-Insulin Hypoglycemic Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Non-Insulin Hypoglycemic Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Non-Insulin Hypoglycemic Drug Sales Volume Share by Application (2021-2032) Figure 26. Global Non-Insulin Hypoglycemic Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Non-Insulin Hypoglycemic Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Non-Insulin Hypoglycemic Drug Sales Value Share by Application (2021-2032) Figure 29. Global Non-Insulin Hypoglycemic Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 30. Global Non-Insulin Hypoglycemic Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Non-Insulin Hypoglycemic Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Non-Insulin Hypoglycemic Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Non-Insulin Hypoglycemic Drug Sales Value (2021-2032) & (US$ Million) Figure 34. North America Non-Insulin Hypoglycemic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Non-Insulin Hypoglycemic Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Non-Insulin Hypoglycemic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Non-Insulin Hypoglycemic Drug Sales Value (2021-2032) & (US$ Million) Figure 40. South America Non-Insulin Hypoglycemic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Non-Insulin Hypoglycemic Drug Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Non-Insulin Hypoglycemic Drug Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Alpha Glucosidase Inhibitors
  • Meglitinides
  • Sulfonylureas
  • Thiazolidinediones
  • Biguanides
  • Others
Applications
  • Hospital Pharmacies
  • Retail Pharmacies
Companies covered
  • GSK
  • Takeda
  • Merck
  • Uni-Bio Science Group
  • Eli Lilly
  • Jiangsu Hengrui Medicine
  • Jiangsu Hansoh Pharmaceutical
  • Pfizer
  • Sumitomo Dainippon Pharma
  • Servier
  • Novo Nordisk
  • Luye Pharma Group
  • Intarcia Therapeutics
  • Geropharm
  • Eurofarma
  • Emisphere
  • Dong-A Pharmaceutical
  • Alkem Labs
  • 3SBio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Non-Insulin Hypoglycemic Drug Sales Value (2021-2032)
  4. 1.2.2 Global Non-Insulin Hypoglycemic Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Non-Insulin Hypoglycemic Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Non-Insulin Hypoglycemic Drug Market Dynamics
  1. 2.1 Non-Insulin Hypoglycemic Drug Industry Trends
  2. 2.2 Non-Insulin Hypoglycemic Drug Industry Drivers
  3. 2.3 Non-Insulin Hypoglycemic Drug Industry Opportunities and Challenges
  4. 2.4 Non-Insulin Hypoglycemic Drug Industry Restraints
3 Non-Insulin Hypoglycemic Drug Market by Company
  1. 3.1 Global Non-Insulin Hypoglycemic Drug Company Revenue Ranking in 2025
  2. 3.2 Global Non-Insulin Hypoglycemic Drug Revenue by Company (2021-2026)
  3. 3.3 Global Non-Insulin Hypoglycemic Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Non-Insulin Hypoglycemic Drug Average Price by Company (2021-2026)
  5. 3.5 Global Non-Insulin Hypoglycemic Drug Company Ranking (2024-2026)
  6. 3.6 Global Non-Insulin Hypoglycemic Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Non-Insulin Hypoglycemic Drug Company Product Type and Application
  8. 3.8 Global Non-Insulin Hypoglycemic Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Non-Insulin Hypoglycemic Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Non-Insulin Hypoglycemic Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Non-Insulin Hypoglycemic Drug Market by Type
  1. 4.1 Non-Insulin Hypoglycemic Drug Type Introduction
  2. 4.1.1 Alpha Glucosidase Inhibitors
  3. 4.1.2 Meglitinides
  4. 4.1.3 Sulfonylureas
  5. 4.1.4 Thiazolidinediones
  6. 4.1.5 Biguanides
  7. 4.1.6 Others
  8. 4.2 Global Non-Insulin Hypoglycemic Drug Sales Volume by Type
  9. 4.2.1 Global Non-Insulin Hypoglycemic Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Non-Insulin Hypoglycemic Drug Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Non-Insulin Hypoglycemic Drug Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Non-Insulin Hypoglycemic Drug Sales Value by Type
  13. 4.3.1 Global Non-Insulin Hypoglycemic Drug Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Non-Insulin Hypoglycemic Drug Sales Value by Type (2021-2032)
  15. 4.3.3 Global Non-Insulin Hypoglycemic Drug Sales Value Share by Type (2021-2032)
5 Non-Insulin Hypoglycemic Drug Market by Application
  1. 5.1 Non-Insulin Hypoglycemic Drug Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Retail Pharmacies
  4. 5.2 Global Non-Insulin Hypoglycemic Drug Sales Volume by Application
  5. 5.2.1 Global Non-Insulin Hypoglycemic Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Non-Insulin Hypoglycemic Drug Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Non-Insulin Hypoglycemic Drug Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Non-Insulin Hypoglycemic Drug Sales Value by Application
  9. 5.3.1 Global Non-Insulin Hypoglycemic Drug Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Non-Insulin Hypoglycemic Drug Sales Value by Application (2021-2032)
  11. 5.3.3 Global Non-Insulin Hypoglycemic Drug Sales Value Share by Application (2021-2032)
6 Non-Insulin Hypoglycemic Drug Regional Sales and Value Analysis
  1. 6.1 Global Non-Insulin Hypoglycemic Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Non-Insulin Hypoglycemic Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Non-Insulin Hypoglycemic Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Non-Insulin Hypoglycemic Drug Sales by Region (2027-2032)
  5. 6.3 Global Non-Insulin Hypoglycemic Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Non-Insulin Hypoglycemic Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Non-Insulin Hypoglycemic Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Non-Insulin Hypoglycemic Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Non-Insulin Hypoglycemic Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Non-Insulin Hypoglycemic Drug Sales Value (2021-2032)
  12. 6.6.2 North America Non-Insulin Hypoglycemic Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Non-Insulin Hypoglycemic Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Non-Insulin Hypoglycemic Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Non-Insulin Hypoglycemic Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Non-Insulin Hypoglycemic Drug Sales Value (2021-2032)
  21. 6.9.2 South America Non-Insulin Hypoglycemic Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Non-Insulin Hypoglycemic Drug Sales Value Share by Country, 2025 VS 2032
7 Non-Insulin Hypoglycemic Drug Country-level Sales and Value Analysis
  1. 7.1 Global Non-Insulin Hypoglycemic Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Non-Insulin Hypoglycemic Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Non-Insulin Hypoglycemic Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Non-Insulin Hypoglycemic Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Non-Insulin Hypoglycemic Drug Sales by Country (2027-2032)
  6. 7.4 Global Non-Insulin Hypoglycemic Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Non-Insulin Hypoglycemic Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Non-Insulin Hypoglycemic Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Non-Insulin Hypoglycemic Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Non-Insulin Hypoglycemic Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Non-Insulin Hypoglycemic Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Non-Insulin Hypoglycemic Drug Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Non-Insulin Hypoglycemic Drug Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Non-Insulin Hypoglycemic Drug Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Uni-Bio Science Group
  20. 8.4.1 Uni-Bio Science Group Company Information
  21. 8.4.2 Uni-Bio Science Group Business Overview
  22. 8.4.3 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Uni-Bio Science Group Non-Insulin Hypoglycemic Drug Product Portfolio
  24. 8.4.5 Uni-Bio Science Group Recent Developments
  25. 8.5 Eli Lilly
  26. 8.5.1 Eli Lilly Company Information
  27. 8.5.2 Eli Lilly Business Overview
  28. 8.5.3 Eli Lilly Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Eli Lilly Non-Insulin Hypoglycemic Drug Product Portfolio
  30. 8.5.5 Eli Lilly Recent Developments
  31. 8.6 Jiangsu Hengrui Medicine
  32. 8.6.1 Jiangsu Hengrui Medicine Company Information
  33. 8.6.2 Jiangsu Hengrui Medicine Business Overview
  34. 8.6.3 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Jiangsu Hengrui Medicine Non-Insulin Hypoglycemic Drug Product Portfolio
  36. 8.6.5 Jiangsu Hengrui Medicine Recent Developments
  37. 8.7 Jiangsu Hansoh Pharmaceutical
  38. 8.7.1 Jiangsu Hansoh Pharmaceutical Company Information
  39. 8.7.2 Jiangsu Hansoh Pharmaceutical Business Overview
  40. 8.7.3 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Jiangsu Hansoh Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
  42. 8.7.5 Jiangsu Hansoh Pharmaceutical Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Non-Insulin Hypoglycemic Drug Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 Sumitomo Dainippon Pharma
  50. 8.9.1 Sumitomo Dainippon Pharma Company Information
  51. 8.9.2 Sumitomo Dainippon Pharma Business Overview
  52. 8.9.3 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sumitomo Dainippon Pharma Non-Insulin Hypoglycemic Drug Product Portfolio
  54. 8.9.5 Sumitomo Dainippon Pharma Recent Developments
  55. 8.10 Servier
  56. 8.10.1 Servier Company Information
  57. 8.10.2 Servier Business Overview
  58. 8.10.3 Servier Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Servier Non-Insulin Hypoglycemic Drug Product Portfolio
  60. 8.10.5 Servier Recent Developments
  61. 8.11 Novo Nordisk
  62. 8.11.1 Novo Nordisk Company Information
  63. 8.11.2 Novo Nordisk Business Overview
  64. 8.11.3 Novo Nordisk Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Novo Nordisk Non-Insulin Hypoglycemic Drug Product Portfolio
  66. 8.11.5 Novo Nordisk Recent Developments
  67. 8.12 Luye Pharma Group
  68. 8.12.1 Luye Pharma Group Company Information
  69. 8.12.2 Luye Pharma Group Business Overview
  70. 8.12.3 Luye Pharma Group Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Luye Pharma Group Non-Insulin Hypoglycemic Drug Product Portfolio
  72. 8.12.5 Luye Pharma Group Recent Developments
  73. 8.13 Intarcia Therapeutics
  74. 8.13.1 Intarcia Therapeutics Company Information
  75. 8.13.2 Intarcia Therapeutics Business Overview
  76. 8.13.3 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Intarcia Therapeutics Non-Insulin Hypoglycemic Drug Product Portfolio
  78. 8.13.5 Intarcia Therapeutics Recent Developments
  79. 8.14 Geropharm
  80. 8.14.1 Geropharm Company Information
  81. 8.14.2 Geropharm Business Overview
  82. 8.14.3 Geropharm Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Geropharm Non-Insulin Hypoglycemic Drug Product Portfolio
  84. 8.14.5 Geropharm Recent Developments
  85. 8.15 Eurofarma
  86. 8.15.1 Eurofarma Company Information
  87. 8.15.2 Eurofarma Business Overview
  88. 8.15.3 Eurofarma Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Eurofarma Non-Insulin Hypoglycemic Drug Product Portfolio
  90. 8.15.5 Eurofarma Recent Developments
  91. 8.16 Emisphere
  92. 8.16.1 Emisphere Company Information
  93. 8.16.2 Emisphere Business Overview
  94. 8.16.3 Emisphere Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Emisphere Non-Insulin Hypoglycemic Drug Product Portfolio
  96. 8.16.5 Emisphere Recent Developments
  97. 8.17 Dong-A Pharmaceutical
  98. 8.17.1 Dong-A Pharmaceutical Company Information
  99. 8.17.2 Dong-A Pharmaceutical Business Overview
  100. 8.17.3 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Dong-A Pharmaceutical Non-Insulin Hypoglycemic Drug Product Portfolio
  102. 8.17.5 Dong-A Pharmaceutical Recent Developments
  103. 8.18 Alkem Labs
  104. 8.18.1 Alkem Labs Company Information
  105. 8.18.2 Alkem Labs Business Overview
  106. 8.18.3 Alkem Labs Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Alkem Labs Non-Insulin Hypoglycemic Drug Product Portfolio
  108. 8.18.5 Alkem Labs Recent Developments
  109. 8.19 3SBio
  110. 8.19.1 3SBio Company Information
  111. 8.19.2 3SBio Business Overview
  112. 8.19.3 3SBio Non-Insulin Hypoglycemic Drug Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 3SBio Non-Insulin Hypoglycemic Drug Product Portfolio
  114. 8.19.5 3SBio Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Non-Insulin Hypoglycemic Drug Value Chain Analysis
  2. 9.1.1 Non-Insulin Hypoglycemic Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Non-Insulin Hypoglycemic Drug Sales Mode & Process
  6. 9.2 Non-Insulin Hypoglycemic Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Non-Insulin Hypoglycemic Drug Distributors
  9. 9.2.3 Non-Insulin Hypoglycemic Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst